Protagonist Therapeutics, Inc. research snapshot
PTGX AI stock analysis currently reads Protagonist Therapeutics as a late-stage biotechnology royalty and milestone business rather than a mature earnings compounder. PTGX closed at $131.42 on July 10, 2026, implying a market value of about $8.45 billion. The company reported $46.02 million of 2025 license and collaboration revenue and a GAAP net loss of $130.15 million, while Q1 2026 revenue rose to $56.37 million and net income was $3.78 million after a $50 million JNJ milestone tied to FDA approval of ICOTYDE. The central PTGX AI stock forecast question is whether ICOTYDE royalties and rusfertide milestones can justify the valuation after Protagonist opted out of Takeda's U.S. profit-sharing structure. This page is informational research, not investment advice.
Current price
$131.42 close on July 10, 2026
Market cap
$8.45 billion reported, or $8.452 billion calculated from $131.42 x 64.31 million shares with a 0.02% variance
AI score
58 / 100
Rating
High-upside, catalyst-driven biotech with two partnered late-stage assets, but binary regulatory, commercialization, and valuation risks keep confidence moderate
Trend status
Long-term price trend remains strong, while short-term momentum is neutral to weak after a volatile July pullback
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Protagonist discovers and advances peptide medicines, then uses partnerships to fund development and monetize approvals through milestones and royalties. The model can scale with successful assets, but revenue is episodic and concentrated. | High |
| Moat | The moat is built from peptide discovery know-how, clinical data, intellectual property, regulatory progress, and partner capabilities. It is asset-specific rather than a broad customer or distribution network moat. | Medium |
| Management | CEO Dinesh V. Patel and CFO Asif Ali have preserved a large liquidity position while advancing partnered assets and expanding wholly owned programs. The major capital allocation test is whether the Takeda opt-out improves risk-adjusted economics without forcing expensive commercialization spending. | Medium |
| Financial trend | 2025 revenue fell 89% to $46.02 million after the 2024 upfront and milestone cycle, and GAAP net loss was $130.15 million. Q1 2026 revenue was $56.37 million with $3.78 million of net income, but the quarter included a $50 million JNJ milestone and should not be annualized mechanically. | High |
| Valuation | At $131.42, trailing GAAP EPS is negative, P/FCF was about 149x using FY2025 FCF per share, and P/S was about 183x using FY2025 revenue per share. StockAnalysis lists 2026 forward non-GAAP EPS of $4.19, so the valuation depends heavily on future milestones, royalties, and launch assumptions. | High |
| Technical trend | Recent price action is extended over the last several months but pulled back 4.52% on July 10. ChartMill shows a positive long-term trend, neutral short-term trend, RSI 41.26, negative MACD, and medium 3.74% ATR, with stale support and resistance zones that need live confirmation. | Medium |
| Risk level | Risk is high. The valuation can re-rate sharply on FDA decisions, label restrictions, clinical data, launch demand, partner choices, royalty timing, dilution, and concentration in a small number of programs. | High |
| AI confidence | The research has strong support for disclosed facts, but scenario outputs are sensitive to non-GAAP forward EPS, milestone timing, royalty assumptions, and the market multiple assigned to a biotech royalty stream. | Medium |
| Investment certainty | Investment certainty is lower than AI confidence. The business may create substantial value if both lead assets commercialize well, but a single regulatory, clinical, or commercial setback could change the thesis quickly. | Low-medium |
PTGX AI stock forecast
The PTGX AI stock forecast uses a three-year sensitivity exercise with StockAnalysis's 2026 forward non-GAAP EPS estimate of $4.19 as the starting point. With annual EPS growth of 25%, 10%, and negative 20% and terminal P/E assumptions of 35x, 25x, and 15x, financial_rigor.py produced reference values of $286.40, $139.40, and $32.20. These are scenario outputs, not analyst targets or promises. The model is especially fragile because the EPS anchor is non-GAAP and the company remains dependent on contingent revenue.
$200 to $286 sensitivity reference
More likely if rusfertide receives FDA approval without a material label limitation, ICOTYDE launches successfully through JNJ, royalties grow, additional indications expand the opportunity, and Protagonist converts milestones into durable per-share cash flow without excessive dilution.
$120 to $160 sensitivity reference
More likely if ICOTYDE royalties build gradually, rusfertide approval and milestone timing are broadly successful, but commercial uptake and the royalty stream take time. The base case assumes the market applies a moderate multiple to forward non-GAAP earnings rather than trailing GAAP earnings.
$25 to $60 sensitivity reference
More likely if rusfertide is delayed or rejected, ICOTYDE uptake disappoints, a label or safety issue limits sales, partner priorities change, clinical programs consume cash, or the market stops capitalizing contingent milestones as recurring earnings.
PTGX AI technical analysis
PTGX AI technical analysis starts from the $131.42 July 10, 2026 close. StockAnalysis historical data shows a July 10 low of $130.64, a July 9 close of $137.64, a July 7 high of $141.08, a June 26 low of $118.31, and a June 8 low of $96.70. ChartMill reports a positive rising 200-day trend, price below a rising 50-day average, a declining 20-day average, RSI 41.26, MACD -0.83, Stochastics 19.98, and ATR 3.74%. Its published support at $65.36 and $50.31 and resistance zone at $83.24 to $85.09 appear stale versus the current price, so they are not treated as live levels.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $131.42 | StockAnalysis closing quote on July 10, 2026. The session range was $130.64 to $137.12 and volume was 946,080 shares. |
| Immediate support reference | $130.64 to $131.42 | The July 10 low and close form the nearest recent price-action reference. A break below this area would show that the latest pullback is extending, not that a durable floor has formed. |
| Intermediate support reference | $118.31 to $122.48 | This zone covers the June 26 low and June 30 close. It is a historical reference from the current data cutoff, not a guaranteed support level. |
| Near resistance reference | $137.64 to $141.10 | The July 9 close and July 7 high mark the nearest recent rejection area. A sustained break above it would require volume and catalyst confirmation. |
| Longer-term support reference | $96.70 to $105.87 | This range covers the June 8 low and June 9 close. It is a deeper reference if the July move reverses and should not be confused with a valuation floor. |
| Moving averages | 20-day declining; 50-day rising; 200-day rising | ChartMill showed price below the 20-day and 50-day averages but above the rising 200-day average on its indexed technical snapshot. Exact values were not exposed in the page data. |
| Momentum | RSI 41.26; MACD -0.83; Stochastics 19.98 | The indicators were neutral to weak, with Stochastics in oversold territory. They describe recent price behavior and do not predict regulatory outcomes. |
| Volume and volatility | 946,080 shares on July 10; ATR 3.74% | July 7 volume reached 1,374,348 shares versus 946,080 on July 10. ChartMill classified ATR as medium volatility, while biotech catalysts can create larger gaps. |
| Invalidation reference | Sustained close below $118.31 | A close below the June 26 low would weaken the recent trend structure. A close below $96.70 would mark a much deeper deterioration, subject to new clinical or regulatory information. |
PTGX AI trading strategy
The PTGX AI trading strategy is a rules-based research framework, not personalized advice. It should be paired with a live chart, an FDA and earnings calendar, position sizing, and fresh SEC filings because PTGX can gap on clinical, regulatory, partner, and milestone news.
Wait for price to reclaim and hold the $137.64 to $141.10 recent resistance reference with sustained volume, then confirm that the catalyst path is improving. A breakout without clarity on rusfertide approval, ICOTYDE launch, or royalty economics is not enough by itself.
A failed breakout followed by a close below $130.64 weakens the short-term setup. A sustained close below $118.31 is a broader trend warning.
If price holds the $118.31 to $122.48 zone, monitor whether the pullback is accompanied by unchanged regulatory milestones, positive partner launch data, stable cash, and no new dilution. The setup is only a test of risk and reward, not a reason to buy a falling stock.
Do not average down solely because price reaches a historical level. Reassess immediately if FDA timing, safety data, partner strategy, cash use, or share count worsens.
Track rusfertide FDA action and label, ICOTYDE prescription and royalty trends, JNJ and Takeda milestone receipts, royalties by indication, cash runway, R&D spending, share count, PN-881 progress, and the obesity pipeline.
Reduce confidence if revenue remains milestone-heavy, royalties lag launch expectations, new programs expand cash burn without validation, or the company needs capital at an unfavorable price.
Investment research summary
Protagonist creates value by discovering and advancing peptide medicines, then partnering with larger companies that can fund late-stage development, regulatory work, and global commercialization. Customers are not the direct payer today. The economic customer is the pharmaceutical partner that pays for access to differentiated drug candidates and future commercial rights.
The moat is asset-level intellectual property, peptide design and development know-how, clinical evidence, regulatory progress, and partner relationships with JNJ and Takeda. It can be valuable when a candidate succeeds, but it is not a permanent corporate moat. Patent life, competing therapies, safety findings, and clinical reproducibility can narrow it quickly.
The failure path is concentrated: rusfertide could face a delay, rejection, narrow label, or weak adoption; ICOTYDE royalties could arrive slower than investors expect; partners could change priorities; and wholly owned programs could consume cash without producing a clinical winner. The stock can fall even after good science if the market had already priced in approval and launch success.
Dinesh V. Patel serves as President and CEO, and Asif Ali serves as Executive Vice President and CFO. The April 2026 Takeda opt-out exchanged U.S. profit-sharing exposure for a $200 million payment, a possible additional $200 million approval payment, enhanced milestones, and 14% to 29% worldwide royalties. The key test is whether this reduces operating risk while preserving upside without excessive dilution.
The long-term opportunity spans targeted oral immunology, rare hematology, obesity medicines, and peptide drug delivery. Oral peptides could address convenience and access, while partnered commercialization can extend reach. The industry is attractive but crowded, and clinical differentiation, reimbursement, safety, manufacturing, and regulatory execution determine who captures value.
At $131.42, PTGX trades on future success rather than current GAAP earnings. The financial_rigor.py check produced negative trailing P/E, about 13.59x book value, about 149x FY2025 FCF per share, and about 183x FY2025 revenue per share. The margin of safety must therefore come from cash, partnered economics, and the probability-weighted value of approvals, not from current operating multiples.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| PTGX closing price and recent volume | $131.42 close on July 10, 2026; 946,080 shares traded | StockAnalysis historical price data | July 12, 2026 |
| Market cap and shares | $8.45B market cap; 64.31M shares outstanding | StockAnalysis statistics and market-cap calculation | July 12, 2026 |
| FY2025 revenue and net income | $46.02M revenue; $130.15M GAAP net loss | SEC 2025 Form 10-K and StockAnalysis financials | July 12, 2026 |
| FY2025 operating cash flow and free cash flow | $57.67M operating cash flow; $56.08M free cash flow | StockAnalysis cash flow statement | July 12, 2026 |
| Cash and marketable securities | $646.0M at December 31, 2025; $620.3M at March 31, 2026 | SEC 2025 Form 10-K and Q1 2026 Form 10-Q | July 12, 2026 |
| Q1 2026 results | $56.37M collaboration revenue; $3.78M net income; $50M JNJ milestone | SEC Q1 2026 Form 10-Q | July 12, 2026 |
| ICOTYDE economics | FDA approved in March 2026; 6% to 10% worldwide royalties and up to $580M future milestones | Protagonist Q1 2026 corporate update | July 12, 2026 |
| Rusfertide regulatory and opt-out terms | NDA priority review; $200M opt-out payment, possible $200M approval payment, and 14% to 29% worldwide royalties | SEC Q1 2026 Form 10-Q and Takeda FDA update | July 12, 2026 |
| Forward earnings reference | 2026 average forecast revenue $510.13M and non-GAAP EPS $4.19 | StockAnalysis analyst forecast page | July 12, 2026 |
| Technical snapshot | RSI 41.26; MACD -0.83; ATR 3.74%; rising 200-day trend signal | ChartMill technical analysis | July 12, 2026 |
This PTGX AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of returns. Forecast ranges are scenario outputs based on available data and assumptions that can be wrong. Verify current prices, filings, clinical and regulatory updates, technical levels, tax rules, and personal suitability before making any financial decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
